Abstract Number: 1526 • 2017 ACR/ARHP Annual Meeting
Shift Analysis of Spinal Radiographic Progression after 2 Years of Secukinumab in Ankylosing Spondylitis – Detailed Results from a Phase 3 Trial
Background/Purpose: An overall low rate of spinal radiographic progression with the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) was reported with secukinumab (SEC), a fully…Abstract Number: 1527 • 2017 ACR/ARHP Annual Meeting
Do TNF Inhibitors Alter the Natural History of Ankylosing Spondylitis By Impacting the Incidence and Prevalence of Comorbidities and Extra-Articular Manifestations?
Background/Purpose: Treatment with TNF inhibitors (TNFi) has led to a reduction in signs and symptoms, and improvement in physical function and quality of life in…Abstract Number: 1528 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Rapid and Sustained Pain Relief in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels and Correlated with Improvement in Fatigue
Background/Purpose: Secukinumab has demonstrated sustained efficacy in patients (pts) with active AS.1,2 We investigated improvement in pain and fatigue scores from baseline (BL) through Week…Abstract Number: 1529 • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Consistent Safety over Long-Term Exposure (up to 3 years) in Patients with Active Ankylosing Spondylitis: Pooled Analysis of Three Phase 3 Trials
Background/Purpose: Secukinumab has demonstrated a consistent and reliable safety profile in three Phase 3 studies in ankylosing spondylitis (AS): MEASURE 1 (NCT01358175), MEASURE 2 (NCT01649375),…Abstract Number: 1530 • 2017 ACR/ARHP Annual Meeting
Improvements in Sleep Problems and Pain in Patients with Active Ankylosing Spondylitis Treated with Intravenous Golimumab: 28-Week Results of the Phase III Trial
Background/Purpose: To investigate the effect of intravenously administered (IV) golimumab (GLM, 2 mg/kg), an anti-TNFα monoclonal antibody, on sleep problems, total back pain (TBP), and…Abstract Number: 1531 • 2017 ACR/ARHP Annual Meeting
Effects of Intravenous Golimumab on Patient-Reported Outcomes in Active Ankylosing Spondylitis: 28-Week Results of the Phase 3 Trial
Background/Purpose: To evaluate patient-reported outcomes (PRO) of physical functioning, mental health functioning, health state, and health-related quality of life (HRQoL) in patients (pts) with active…Abstract Number: 1532 • 2017 ACR/ARHP Annual Meeting
Safety and Efficacy of Intravenous Golimumab in Adult Patients with Active Ankylosing Spondylitis: Results through 1 Year
Background/Purpose: Subcutaneous (SC) golimumab (GLM) is currently approved for adult patients (pts) with RA, PsA, and AS. The GO-ALIVE study was designed to evaluate the…Abstract Number: 1533 • 2017 ACR/ARHP Annual Meeting
Efficacy of Switching Biological Dmards in Patients with Axial Spondyloarthritis: Results from a Systematic Literature Review
Background/Purpose: Approximately 30-50% of patients with axial SpA (axSpA) who receive a first bDMARD do not respond well. Current practice in these patients is switching…Abstract Number: 1534 • 2017 ACR/ARHP Annual Meeting
Comparison of Long Term Anti-Tnf Survival in Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis; Data from Turkbio Registry
Background/Purpose: Limited data are available on anti-TNF survival in non-radiographic axial spondyloarthritis (nr-axSpA) patients and their long-term survival in ankylosing spondylitis (AS). The aim of…Abstract Number: 1535 • 2017 ACR/ARHP Annual Meeting
Study of Potential Clinical and Biologic Predictors of Maintaining Good Response at 1 Year Follow-up, in Patients with Ankylosing Spondylitis Under Dose Reduction of TNFi Treatment
Background/Purpose: Some clinical guidance recommends empirical TNFi dose reductions in AS patients despite lack of robust supportive evidence. Recently, we communicated that a strategy of…Abstract Number: 1536 • 2017 ACR/ARHP Annual Meeting
Patient Preferences in Medication for Treatment of Spondyloarthritis: A Qualitative Study
Background/Purpose: Medications used in the treatment of spondyloarthritis (SpA) include nonsteroidal anti-inflammatory drugs (NSAIDs) and biologics, with each class having distinct characteristics that patients may…Abstract Number: 1537 • 2017 ACR/ARHP Annual Meeting
Determinants of Patient-Reported Improvement after Administration of Biological Treatment in Axial Spondyloarthritis: A Cross-Sectional Study
Background/Purpose: Efficacy of biological treatment in patients with axial spondyloarthritis (SpA) varies and is dependent on both disease-related and patient-related factors. The goal of this…Abstract Number: 1538 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Early Versus Delayed Anti-TNF-α Treatment in Axial Spondyloarthritis
Background/Purpose: Anti-TNF-α agents are the mainstay of pharmacotherapy for patients with axial spondyloarthritis (AxSpA) who failed treatment with NSAIDs. A little is known about the…Abstract Number: 1539 • 2017 ACR/ARHP Annual Meeting
High Retention Rate and Sustained Responses with Secukinumab 150mg in Patients with Active Ankylosing Spondylitis: 3-Year Results from a Phase 3 Study
Background/Purpose: Secukinumab provided sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) over 2 years in the MEASURE 2 study (NCT01649375).1,2 Here we…Abstract Number: 1540 • 2017 ACR/ARHP Annual Meeting
Comparison of Radiologic Parameters of Ankylosing Spondylitis Treated with Anti-TNF-α Versus Non-Steroidal Anti-Inflammatory Drugs and Sulfasalazine
Background/Purpose: There are many studies about impact of TNF-inhibitors on radiographic progression but little data are available on the relationship between treatment agents and sagittal…
ACR Meeting Abstracts